Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Olaparib

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 2 (1)

Trial Status

Completed1
Unknown1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06767046Phase 1Active Not Recruiting

KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

NCT01078662Phase 2Completed

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

NCT06108531UnknownPrimary

Tumor Exosome Liquid Biopsy Strategy to Diagnose Pancreatic Cancer

Showing all 3 trials

Research Network

Common Treatments

  • Olaparib1
  • Krasspecific Autologous Tcrt Cell Injection1

Active Sponsors

  • AstraZeneca1
  • Corregene Biotechnology Co., Ltd1
  • Shanghai Jiao Tong University School of Medicine1

Top Investigators

Related Conditions

  • Colorectal1
  • Breast1
  • Nonsmall Cell Lung Cancer Nsclc1
  • Ovarian1
  • Prostate1

Activity Timeline